Editing Hashimoto's thyroiditis (section)

==== Reverse T<sub>3</sub> ====
Measuring [[Reverse triiodothyronine|reverse tri-iodothyronine]] (rT<sub>3</sub>) is often mentioned in the lay (non-medical) press as a possible marker to inform T<sub>4</sub> or T<sub>3</sub> therapy, "however, there is currently no evidence to support this application" as of 2023.<ref name="Van Uytfanghe-2023" /> Although cited in the lay press as a possible competitor to T<sub>3</sub>, it is unlikely that rT<sub>3</sub> causes hypothyroid symptoms by out-competing T<sub>3</sub> for [[Thyroid hormone receptor|thyroid hormone receptors]], as it has a binding affinity 200 times weaker.<ref name="Halsall-2021" /> It is also unlikely that rT<sub>3</sub> causes poor T<sub>4</sub> to T<sub>3</sub> conversion; despite being demonstrated ''[[in vivo]]'' to have the potential to inhibit [[Iodothyronine deiodinase|DIO]]-mediated T<sub>4</sub> to T<sub>3</sub> conversion, this is considered improbable at normal body hormone concentrations.<ref name="Halsall-2021">{{cite journal | vauthors = Halsall DJ, Oddy S | title = Clinical and laboratory aspects of 3,3',5'-triiodothyronine (reverse T3) | journal = Annals of Clinical Biochemistry | volume = 58 | issue = 1 | pages = 29–37 | date = January 2021 | pmid = 33040575 | doi = 10.1177/0004563220969150 }}</ref>